Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab in Japanese patients with advanced gastric cancer
NCT05913115Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemarituzumab in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Amgen. Primary endpoints: Dose-limiting Toxicities, Area Under Serum Concentration-time Curve and 5 more. Started Jun 2017; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05913115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913115.